Data in Lancet Oncology discloses lower toxicity for Accuray Cyberknife patients
Accuray announces that The Lancet Oncology has published patient- and clinician-reported outcomes data from the PACE - Prostate Advances in Comparative Evidence - trial in its most recent issue. While further investigation is planned, data reported in the journal indicate that the level of grade 2 or higher acute genitourinary toxicity in the stereotactic body radiation therapy, or SBRT, arm of the trial is lower for patients treated with the Accuray CyberKnife System than it is for patients treated on a conventional linear accelerator. conventional radiation treatments. In the PACE trial, SBRT was delivered in five sessions while conventional radiation therapy was delivered in 20 or 39 sessions. Both the patient- and clinician-reported toxicity data demonstrate that despite the high dose delivered to the prostate, use of SBRT and conventional radiation therapy resulted in comparable rates of acute gastrointestinal and genitourinary toxicity.